Merck KGaA
Diatech Pharmacogenetics, Merck KGaA Expand RAS Biomarker Testing Pact in Middle East, Africa
The companies are collaborating to improve access to biomarker testing to inform the use of targeted therapies in colorectal cancer across the region.
Foundation Medicine Companion Dx Test Gets FDA OK for Use with Merck's Tepmetko in Lung Cancer
The blood-based comprehensive genomic profiling test uses next-generation sequencing to analyze 324 genes.
Biocartis, Merck KGaA Extend RAS Testing Partnership to Middle East, North Africa
The companies hope to improve access to biomarker testing to direct more personalized treatment for cancer patients in the region.
Top Five Articles on 360Dx Last Week: Coverage of Cancer Tests Rescinded; FDA Clearances; and More
Last week, readers were most interested in a story about Medicare Administrative Contractor Novitas rescinding its coverage for several cancer genetic tests.
Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.